Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2003
04/10/2003WO2003029292A2 Gene regulatory peptides
04/10/2003WO2003029291A2 Pegylated and diglycosylated erythropoietin
04/10/2003WO2003029290A1 Drug transporter and use thereof
04/10/2003WO2003029289A2 Fragements of heat shock proteins and their use
04/10/2003WO2003029288A2 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same
04/10/2003WO2003029284A1 Anti-hiv agent
04/10/2003WO2003029283A2 Genetic sequences related to bone diseases in the osteopetrotic grey-lethal (gl) mouse
04/10/2003WO2003029282A2 Tumor-peptide antigens from the human prdi-bf1-protein
04/10/2003WO2003029281A1 An sil-6r/il-6 fusion protein cooperates synergistically with hgf to stimulate hepatocyte proliferation in vivo
04/10/2003WO2003029279A2 Immunodominant acetylcholine receptor alpha subunit peptide: mhc complexes
04/10/2003WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use
04/10/2003WO2003029275A2 Anti-angiogenic peptides
04/10/2003WO2003029270A2 Process for preparing glycopeptide phosphonate derivatives
04/10/2003WO2003029266A1 Antisense modulation of vascular endothelial growth factor receptor-2 expression
04/10/2003WO2003028858A1 Process for ultrafiltration of an antifungal agent
04/10/2003WO2003028840A2 Combined compositions and methods for tumor vasculature coagulation and treatment
04/10/2003WO2003028768A1 Remedies
04/10/2003WO2003028763A1 Inhibition of neonatal hyperbilirubinemia in breast fed infants
04/10/2003WO2003028756A2 An in vivo animal model of chronic arterial occlusion and use of collagenase to facilitate guide wire crossing in chronic arterial occlusions
04/10/2003WO2003028755A1 Method for treating hepatitis c virus infection in treatment failure patients
04/10/2003WO2003028754A1 Method for treating hepatitis c virus infection in treatment failure patients
04/10/2003WO2003028753A1 USE OF INTERFERON β IN THE THERAPY OF SYSTEMIC LUPUS ERYTHEMATODES
04/10/2003WO2003028752A1 Csf-1 immunomodulation
04/10/2003WO2003028751A1 Glycoprotein and/or glycomacropeptide containing ophthalmic preparation
04/10/2003WO2003028750A1 Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
04/10/2003WO2003028743A1 Storage-stable fibrinogen solutions
04/10/2003WO2003028722A1 Treatment of hepatitis b virus infection with human monoclonal antibodies
04/10/2003WO2003028666A2 Isolated polypeptides and compositions from the venom of p. transvaalicus and methods of use
04/10/2003WO2003028659A2 Methods and compositions for modulating apoptosis
04/10/2003WO2003028657A2 Compositions for oral gene therapy and methods of using same
04/10/2003WO2003028656A2 Adjuvant compositions
04/10/2003WO2003028654A2 Storage-stable human fibrinogen solutions
04/10/2003WO2003028646A2 Methods of treating drug-resistant bacterial infections
04/10/2003WO2003028637A2 Antisense modulation of sphingosine-1-phosphate lyase expression
04/10/2003WO2003028636A2 Antisense modulation of il-1 receptor-associated kinase-4 expression
04/10/2003WO2003028634A2 Method of treatment using ligand-immunogen conjugates
04/10/2003WO2003028633A2 Parenteral delivery systems
04/10/2003WO2003028630A2 Methods and compositions for modulating interleukin-21 receptor activity
04/10/2003WO2003028626A2 Glucagon-like peptides (glp-1) and treatment of respiratory distress
04/10/2003WO2003028621A2 Proteinase inhibitors for treating and diagnosing neurodegenerative diseases
04/10/2003WO2003028590A1 Rational drug therapy device and methods
04/10/2003WO2003028545A2 Method, instruments, and kit for autologous transplantation
04/10/2003WO2003028537A2 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
04/10/2003WO2003028536A2 Methods for diagnosing and treating heart disease
04/10/2003WO2003028527A2 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
04/10/2003WO2003028476A1 Novel enzyme compositions for poultry
04/10/2003WO2003028441A1 Gene therapy for the prevention of autoimmune disease
04/10/2003WO2003015711A9 Combination motif immune stimulatory oligonucleotides with improved activity
04/10/2003WO2003014326A3 Isolation and mobilization of stem cells expressing vegfr-1
04/10/2003WO2003012033A3 Antisense modulation of short heterodimer partner-1 expression
04/10/2003WO2003011300B1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
04/10/2003WO2003006056A3 End-locked five-helix protein
04/10/2003WO2003005812A3 Modulation of metabolism of steroids and xenobiotics
04/10/2003WO2003004527A3 Novel neurotrophic factors
04/10/2003WO2003004518A3 Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors
04/10/2003WO2003002598A3 Peptides for use as translocation factors
04/10/2003WO2003002103A3 Hydrophobic dopamine agonists administered to the dermis
04/10/2003WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
04/10/2003WO2003002086A3 Use of the tripeptide lys-pro-val(kpv) for improving the skin barrier function
04/10/2003WO2003000855A3 Chimeric capsid proteins and uses thereof
04/10/2003WO2003000193A3 Covalent coupling of botulinum toxin with polyethylene glycol
04/10/2003WO2003000178A3 Black soybean polysaccharides
04/10/2003WO2002102978A3 Human growth hormone antagonists
04/10/2003WO2002102394A3 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
04/10/2003WO2002099093A3 Provision of a putative human hydroxymethyl-glutaryl-coa lyase-like enzyme
04/10/2003WO2002098448A9 Methods and compositions for modulating ace-2 activity
04/10/2003WO2002098365A3 Conditioned cell culture media and uses thereof
04/10/2003WO2002096467A3 Pharmaceutical use for secreted bacterial effector proteins
04/10/2003WO2002092622A3 Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors
04/10/2003WO2002083103A3 Pharmaceutical product with reticulated crystalline microstructure
04/10/2003WO2002081704A3 Regulation of human protein kinase-like protein
04/10/2003WO2002081504A3 Multimerization of hiv-1 vif protein as a therapeutic target
04/10/2003WO2002080982A9 Nucleic acid mucosal immunization
04/10/2003WO2002080956A3 Use of compounds modulating rxr-ppar heterodimer activity as medicine for treating hepatitis c
04/10/2003WO2002072826A3 Neurotrophic factors
04/10/2003WO2002071827A3 Retinoid x receptor modulators
04/10/2003WO2002070692A3 Abca9 transporter and uses thereof
04/10/2003WO2002070551A3 Neuritogenic compound and uses thereof
04/10/2003WO2002068602A8 Methods for modulating g2a receptor activity
04/10/2003WO2002067969A3 Stabilized insulin formulations
04/10/2003WO2002062958A3 Prc17: an amplified cancer gene
04/10/2003WO2002061082A3 Zis-sr nucleic acid and amino acid sequences involved in the regulated secretory pathway and/or the regulation of the neuroendocrine phenotype (nep)
04/10/2003WO2002060412A3 Stabilised polymeric aerosols for pulmonary gene delivery
04/10/2003WO2002059311A3 Colon cancer marker
04/10/2003WO2002057460A3 Polynucleotides encoding human phosphatases
04/10/2003WO2002055705A3 Proteins and nucleic acids encoding same
04/10/2003WO2002055688A3 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
04/10/2003WO2002055152A3 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
04/10/2003WO2002053169A8 Use of dipeptylpeptidase iv and aminopeptidase-n inhibitors in the treatment of ischaemia-induced neuro-degeneration
04/10/2003WO2002050122A3 Means for the diagnosis and therapy of ctcl
04/10/2003WO2002050107A3 Streptococcus pyogenes antigens and corresponding dna fragments
04/10/2003WO2002044203A3 Production of recombinant bmp-2
04/10/2003WO2002043767A8 Improved oral delivery of peptides using enzyme-cleavable membrane translocators
04/10/2003WO2002043745A3 Histaminase of vegetable origin for use in the treatment of allergic and septic shock and of allergic asthma
04/10/2003WO2002042414A3 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
04/10/2003WO2002040674A3 '67118', '67067' and '62092', human proteins and methods of use thereof
04/10/2003WO2002040666A3 Fat regulated genes, uses thereof, and compounds for modulating same
04/10/2003WO2002036175A3 Sustained release device for treating conditions of the joint
04/10/2003WO2002034766A3 Peptides derived from the human amyloid precursor protein used to protect cells from iron catalyzed oxidative damage
04/10/2003WO2002033058A3 Novel cysteine proteases and uses thereof
1 ... 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 ... 3163